Urinary symptoms occur in 19% of human T-cell lymphotropic virus type 1 (HTLV-1)-infected patients who do not fulfill criteria for HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) and in almost 100% of HAM/TSP patients. Few studies have evaluated therapies for overactive bladder (OAB) caused by HTLV-1 infection. This case report describes the effect of onabotulinum toxin A on the urinary manifestations of three patients with HAM/TSP and OAB symptoms. The patients were intravesically administered 200 units of Botox®. Their incontinence episodes improved, and their OAB symptoms scores (OABSS) reduced significantly. These data indicate that Botox® should be a treatment option for OAB associated with HTLV-1 infection.
CITATION STYLE
Neto, J. A. C., Bittencourt, V. G., de Oliveira, C., Andrade, R., de Carvalho, E. M., & de Carvalho, E. M. (2014). The use of botulinum toxin type A in the treatment of HTLV-1-associated overactive bladder refractory to conventional therapy. Revista Da Sociedade Brasileira de Medicina Tropical, 47(4), 528–532. https://doi.org/10.1590/0037-8682-0029-2014
Mendeley helps you to discover research relevant for your work.